Extensive-stage small-cell lung cancer: Evolution of systemic therapy and future directions

Jeffrey Warren Allen, Mohammad Jahanzeb

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Extensive-stage small-cell lung cancer (ES-SCLC) is one of the most lethal malignancies, with a median overall survival of only 8-10 months with first-line chemotherapy despite response rates of 60%-80%. In the second-line setting, the prognosis is even more limited, with only 20%-30% of patients having a response and a median survival measured in weeks to months. This article will review systemic chemotherapy in first- and second-line treatment of patients with ES-SCLC and discuss novel therapeutic agents, cytotoxic and "targeted, " with an emphasis on recently completed clinical trials and ongoing investigations.

Original languageEnglish (US)
Pages (from-to)262-270
Number of pages9
JournalClinical Lung Cancer
Volume9
Issue number5
DOIs
StatePublished - Sep 2008
Externally publishedYes

Keywords

  • Bortezomib
  • Cytotoxic therapy
  • Epidermal growth factor
  • Etoposide
  • Marimastat
  • Vandetanib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Extensive-stage small-cell lung cancer: Evolution of systemic therapy and future directions'. Together they form a unique fingerprint.

  • Cite this